Duchenne muscular dystrophy: major trials and events to watch in 2023

Duchenne muscular dystrophy: major trials and events to watch in 2023

Source: 
Clinical Trials Arena
snippet: 

In 2023, two potential FDA approvals and three late-stage clinical trial readouts could shift the treatment landscape for Duchenne muscular dystrophy. The upcoming FDA approval decision for Sarepta’s gene therapy SRP-9001, expected by May, headlines what figures to be an eventful year of drug development.